BBIO Q1 2024 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$211M+11461.9% YoY

Gross Profit

$211M99.7% margin

Operating Income

$343,0000.2% margin

Net Income

-$35M-16.7% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+11998.6%

Cash Flow

Operating Cash Flow

-$220M

Free Cash Flow

-$221M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$849M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.0B

Cash & Equivalents

$475M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$211M	$2M	+11461.9%
Gross Profit	$211M	$1M	+17816.8%
Operating Income	$343,000	-$126M	+100.3%
Net Income	-$35M	-$140M	+74.9%